Safety and efficacy of inhaled itraconazole in adults with asthma and allergic bronchopulmonary aspergillosis (PUR1900-ABPA): a randomized, double-blind, parallel group, placebo-controlled, multicenter, phase 2 trial

COMMENTED

Asthma

Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial

★ 3 Recommended by Dr. med. Martin Frey, Faculty Member

★ 2 Recommended and commented by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Wechsler ME, Brightling CE, Brusselle G, Caminati M, Soler T, González EM, Nakwan N, Capala-Szczurko I, Hunter G, Almqvist G, Lal H, Kabelis P, Scrigner P, Matsunaga Y, Molfino N, Ponnarambil SS, SUNRISE study investigators

doi: 10.1016/S2213-2600(26)00076-7

Asthma

Budesonide-formoterol versus terbutaline reliever in adults with asthma using maintenance inhaled corticosteroids in New Zealand (INFORM ASTHMA): an open-label, parallel-group, randomised, controlled, phase 4 trial

Lancet Respir Med

Noble JH, Bean O, Perry M, Sayers R, Cullen R, Black B, Holliday M, Eathorne A, Shortt N, Kirton L, Perry B, Bruce P, Leung W, Pavord ID, Weatherall M, Beasley RW, INFORM ASTHMA collaborators

doi: 10.1016/S2213-2600(25)00327-3

COPD

Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials

Lancet

Papi A, Greening NJ, Bhatt SP, Roche N, Celli B, Wedzicha JA, Agustí À, Tal-Singer R, Han MK, Janssens W, Hanania NA, Nair P, Bremner P, Porpodis K, Shibata Y, Korn S, Yang T, Gordon O, Saenz R, Ng J, Cheung DS, Devine J, Grimbaldeston MA, Zhang W, Yang X, Mohan D, Vogelmeier CF, Brightling CE, ALIENTO and ARNASA investigators

doi: 10.1016/S0140-6736(26)00637-9

COMMENTED

COPD

Summary of Research: Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trials (the ENHANCE Trials)

★ 2 Recommended by Dr. med. Martin Frey, Faculty Member

★ 2 Recommended and commented by Dr Marcus Hesse, Faculty Member

Adv Ther

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Rickard K, O'Donovan K, Sciurba F

doi: 10.1007/s12325-026-03514-6

RECOMMENDED

Asthma

Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials

★ 3 Recommended by Dr. med. Martin Frey, Faculty Member

Lancet Respir Med

Papi A, Wise RA, Jackson DJ, Lugogo N, Chen R, Trasieva T, Obasi C, Movitz C, Helman J, Salter P, Springer K, Bondoc M, Shah M, Knappenberger K, Bowen K, Pandya H, Megally A, Patel M, KALOS and LOGOS study investigators

doi: 10.1016/S2213-2600(25)00457-6

Asthma

Rilzabrutinib for patients with moderate-to-severe asthma with uncontrolled symptoms: a double-blind, placebo-controlled, phase 2 study

Lancet Respir Med

Maspero JF, Pavord ID, Wechsler ME, Busse W, Laidlaw TM, Mróz RM, Liu T, Mikol V, Suratt BT, Gereige J, Mannent L, Martincova R

doi: 10.1016/S2213-2600(25)00439-4

COMMENTED

Asthma

Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: A multicenter, randomized, double-blind, Phase 3A Clinical Trial (NIMBLE)

★ 3 Recommended by Dr. med. Martin Frey, Faculty Member

★ 3 Recommended and commented by Dr Marcus Hesse, Faculty Member

Am J Respir Crit Care Med

Chupp G, Nagase H, Skowasch D, Devouassoux G, Côté A, Jackson DJ, Jackson DJ, Wechsler ME, Imber V, McGinniss JE, K SO, Howarth P, Pavord ID, NIMBLE Study Investigators

doi: 10.1093/ajrccm/aamag031

COMMENTED

Further Publications

Morphine for chronic breathlessness (MABEL) in the UK: a multi-site, parallel-group, dose titration, double-blind, randomised, placebo-controlled trial

★ 3 Recommended and commented by Dr. med. Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Johnson MJ, Williams B, Keerie C, Tuck S, Hart S, Bajwah S, Chaudhuri N, Pearson M, Cohen J, Evans RA, Currow DC, Higginson IJ, Hall P, Atter M, Norrie J, Fallon MT, MABEL collaborative

doi: 10.1016/S2213-2600(25)00205-X

COPD

A phase 2a, double-blind, randomised, placebo-controlled trial of the myeloperoxidase inhibitor, mitiperstat, in participants with chronic obstructive pulmonary disease

Eur Respir J

Saralaya D, Mustapa MN, Ferreira J, Kocks JWH, Brailsford W, Rosengren S, Spata E, Belvisi MG, Leander J, Riff C, De Palo G, Windgassen D, Chalmers JD, Russell REK, Hurst JR, Śmiałowski A, Hughes R

doi: 10.1183/13993003.02567-2025

Related content

Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial

Budesonide-formoterol versus terbutaline reliever in adults with asthma using maintenance inhaled corticosteroids in New Zealand (INFORM ASTHMA): an open-label, parallel-group, randomised, controlled, phase 4 trial

Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials

Summary of Research: Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trials (the ENHANCE Trials)

Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials

Rilzabrutinib for patients with moderate-to-severe asthma with uncontrolled symptoms: a double-blind, placebo-controlled, phase 2 study

Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: A multicenter, randomized, double-blind, Phase 3A Clinical Trial (NIMBLE)

Morphine for chronic breathlessness (MABEL) in the UK: a multi-site, parallel-group, dose titration, double-blind, randomised, placebo-controlled trial

A phase 2a, double-blind, randomised, placebo-controlled trial of the myeloperoxidase inhibitor, mitiperstat, in participants with chronic obstructive pulmonary disease